2003
DOI: 10.1001/archderm.139.7.949
|View full text |Cite
|
Sign up to set email alerts
|

Addition of Low-Dose Methotrexate to Infliximab in the Treatment of a Patient With Severe, Recalcitrant Pustular Psoriasis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
15
0
1

Year Published

2004
2004
2018
2018

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 27 publications
(17 citation statements)
references
References 4 publications
1
15
0
1
Order By: Relevance
“…The infusion was well tolerated without any side effects. Also, Barland et al 31 reported successful treatment of palmoplantar pustular psoriasis with infliximab and methotrexate. No side effects were noted.…”
Section: Discussionmentioning
confidence: 99%
“…The infusion was well tolerated without any side effects. Also, Barland et al 31 reported successful treatment of palmoplantar pustular psoriasis with infliximab and methotrexate. No side effects were noted.…”
Section: Discussionmentioning
confidence: 99%
“…This risk may be reduced either by establishing a regular drug administration rhythm, as we managed to do with our patient, or by associating an immunosuppressant agent to the treatment [9] . For instance, there have been cases in which the addition of methotrexate was sufficient to sustain treatment [10] . In spite of all our care, our patient suffered an episode of severe exacerbation of the pustular psoriasis in the course of the maintenance treatment, which was probably related to the production of these neutralizing antibodies.…”
Section: Commentmentioning
confidence: 99%
“…Patients received a mean total number of treatments of 12 (range, [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]. Patients were followed up for a minimum of 4 months and maximum of 33 months (median, 22 months).…”
Section: Resultsmentioning
confidence: 99%
“…[1][2][3][4][5][6][7][8][9][10] Most of these reports are small case series or individual case reports. [3][4][5][6][7][8][9][10] In the multicenter, placebo-controlled, phase II study (SPIRIT trial) presented by Gottlieb et al, 2 249 patients with moderate to severe plaque psoriasis were randomized to receive placebo, 3 mg/kg, or 5 mg/kg of infliximab at baseline (week 0), 2, and 6 weeks. No concomitant systemic or topical therapies for psoriasis were allowed.…”
Section: Abbreviations Usedmentioning
confidence: 99%
See 1 more Smart Citation